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Rationale: Genetic variance in the 17q21 gene locus is the strongest known genetic determinant for early onset childhood asthma, but has also been associated with uncontrolled asthma despite asthma treatment. The aim of the study was to assess whether there is an association between a single nucleotide polymorphism (SNP) in the 17q21 locus (rs7216389) and asthma exacerbations despite the use of inhaled corticosteroids (ICS) in asthmatic children and young adults.
Methods: We meta-analyzed the association between the variant rs7216389 and exacerbations in 4,156 children and young adults with reported ICS use in twelve studies participating in the multi-ethnic Pharmacogenomics of Childhood Asthma (PiCA) consortium. This meta-analysis includes patients from eight distinct European cohorts; BAMSE (n=122, Sweden), BREATHE (n=806, Scotland, UK), ESTATE (n=102, the Netherlands), followMAGICS (n=155, Germany), PACMAN (n= 530, the Netherlands), PAGES (n=354, Scotland, UK), PASS (n=390, UK) and SLOVENIA (n=199, Slovenia), from one African-American cohort; SAGE II (n=468, USA), from two Latino cohorts; GALA II (n=745, USA), HPR (n=123, USA) and one North-American trial; CAMP (n=172, USA). Two outcome measures were studied: hospitalization/emergency room (ER) visits (available in 12 studies, n= 4,156 patients) and oral corticosteroid (OCS) use (available in 9 studies, n=3,512 patients) in the last 6 or 12 months of the study or first year of the trial. Meta-analyses with random effects were performed using an additive genetic model adjusted for age, gender and adjusted British Thoracic Society (BTS) treatment steps.   
Results: Overall, 1,433 patients reported hospitalizations/ER visits and 1,274 patients reported OCS use. The SNP was statistically significantly associated with an increased risk of OCS use (OR per increase in variant allele= 1.19, 95%CI: 1.02-1.39, p=0.03, I2=40.78%). Regarding the hospitalization / ER visits, the summary effect estimate pointed in the same direction (OR per increase in variant allele= 1.17, 95%CI: 0.96- 1.42, p=0.1, I2=59.44%). 
Conclusions: Variation in the 17q21 locus contributes to an increased risk of exacerbations despite the use of ICS in children and young adults. 

